Efficacy of the Systemic Immune Inflammation Index in Malignant and Benign Parotid Neoplasms.

Creative Commons License

Sahin A., Kars A., Kilic K., Ucar H. B., Sakat M. S.

Cureus, cilt.14, sa.11, 2022 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 11
  • Basım Tarihi: 2022
  • Doi Numarası: 10.7759/cureus.31878
  • Dergi Adı: Cureus
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Anahtar Kelimeler: sii index, systemic immune -inflammation index, parotid mass, malignant tumor, inflammatory&nbsp, parameters, benign parotid tumor, TO-LYMPHOCYTE RATIO, GLAND TUMORS, NEUTROPHIL, SURVIVAL, CANCER, PROGNOSIS, PLATELET
  • Atatürk Üniversitesi Adresli: Evet

Özet

Objective Several studies have looked at systemic immune-inflammation index (SII) (neutrophil x platelet x lymphocyte) values, which have been shown to be useful in determining tumor aggressivity and prognosis, as well as predicting recurrence risk, particularly in cancer cases. The purpose of the current study was to determine SII values in patients with parotid masses and investigate their utility in distinguishing between malignant and benign parotid tumors. Methods This retrospective study included 237 adult patients-112 women and 125 men-who were followed up on and treated for parotid mass between 2015 and 2021. The SII values determined were compared between the groups. Results The difference between the two groups was statistically significant (p = 0.001). In addition, SII values were higher in malignant tumors with perineural and lymphovascular invasion compared to other malignant tumors, although the difference was not statistically significant. Conclusions Although SII values yielded significant results in differentiating malignant from benign parotid tumors, since no significant cut-off value was determined, we do not think that they represent an effective marker capable of being used to distinguish between these tumors in clinical practice.